Expression of the MAGE gene family in human hepatocellular carcinoma

Kouichirou Tahara, Masaki Mori, Noriaki Sadanaga, Yoshihiro Sakamoto, Seigo Kitano, Masatoshi Makuuchi

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

BACKGROUND. The 12 members of the MAGE gene family encode tumor specific antigens that are recognized by autologous cytotoxic T lymphocytes (CTL). The MAGE genes are expressed not only in melanoma but in the other malignant tumors as well. There is, however, little information on their expression in hepatocellular carcinoma (HCC). The authors thus studied the expression of the MAGE gene family in human HCC and discuss the possibility of specific immunotherapy using MAGE peptides. METHODS. Tumor tissue samples of HCC and paired nontumor tissues of the liver were obtained from 22 HCC patients. Total RNA was extracted and cDNA was synthesized. Polymerase chain reaction amplification using each MAGE gene specific primer was then performed to detect the expression of each MAGE gene. Immunoblotting and immunohistochemical analysis were performed to confirm the expression of MAGE-3 gene product in HCC. RESULTS. The expression rate of each MAGE gene was as follows: MAGE-1 and -3 were expressed in approximately 68% of the tumors; MAGE-8 was expressed in 46%; and MAGE-2, -6, -10, -11, and -12 were expressed in approximately 30%. Nineteen (86%) of 22 tumors expressed at least 1 MAGE gene. On the other hand, no expression was detected in the noncarcinomatous liver tissue specimens. Actual expression of the gene product of MAGE-3 was detected in 50% of tumors. Clinicopathologic data on the MAGE positive and negative cases were compared. Significant differences were observed between MAGE expression status and a few clinicopathologic factors; however, further investigation is required to elucidate these correlations completely. CONCLUSIONS. These findings demonstrated that MAGE gene expression is frequent in HCC, thus suggesting that HCC patients may be good candidates for specific immunotherapy using MAGE peptides.

Original languageEnglish
Pages (from-to)1234-1240
Number of pages7
JournalCancer
Volume85
Issue number6
DOIs
Publication statusPublished - Mar 15 1999

Fingerprint

Hepatocellular Carcinoma
Gene Expression
Genes
Neoplasms
Immunotherapy
Peptides
Liver
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Immunoblotting
Melanoma
Complementary DNA
RNA
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Expression of the MAGE gene family in human hepatocellular carcinoma. / Tahara, Kouichirou; Mori, Masaki; Sadanaga, Noriaki; Sakamoto, Yoshihiro; Kitano, Seigo; Makuuchi, Masatoshi.

In: Cancer, Vol. 85, No. 6, 15.03.1999, p. 1234-1240.

Research output: Contribution to journalArticle

Tahara, Kouichirou ; Mori, Masaki ; Sadanaga, Noriaki ; Sakamoto, Yoshihiro ; Kitano, Seigo ; Makuuchi, Masatoshi. / Expression of the MAGE gene family in human hepatocellular carcinoma. In: Cancer. 1999 ; Vol. 85, No. 6. pp. 1234-1240.
@article{356fe899e243427ea43208db7b6ff23e,
title = "Expression of the MAGE gene family in human hepatocellular carcinoma",
abstract = "BACKGROUND. The 12 members of the MAGE gene family encode tumor specific antigens that are recognized by autologous cytotoxic T lymphocytes (CTL). The MAGE genes are expressed not only in melanoma but in the other malignant tumors as well. There is, however, little information on their expression in hepatocellular carcinoma (HCC). The authors thus studied the expression of the MAGE gene family in human HCC and discuss the possibility of specific immunotherapy using MAGE peptides. METHODS. Tumor tissue samples of HCC and paired nontumor tissues of the liver were obtained from 22 HCC patients. Total RNA was extracted and cDNA was synthesized. Polymerase chain reaction amplification using each MAGE gene specific primer was then performed to detect the expression of each MAGE gene. Immunoblotting and immunohistochemical analysis were performed to confirm the expression of MAGE-3 gene product in HCC. RESULTS. The expression rate of each MAGE gene was as follows: MAGE-1 and -3 were expressed in approximately 68{\%} of the tumors; MAGE-8 was expressed in 46{\%}; and MAGE-2, -6, -10, -11, and -12 were expressed in approximately 30{\%}. Nineteen (86{\%}) of 22 tumors expressed at least 1 MAGE gene. On the other hand, no expression was detected in the noncarcinomatous liver tissue specimens. Actual expression of the gene product of MAGE-3 was detected in 50{\%} of tumors. Clinicopathologic data on the MAGE positive and negative cases were compared. Significant differences were observed between MAGE expression status and a few clinicopathologic factors; however, further investigation is required to elucidate these correlations completely. CONCLUSIONS. These findings demonstrated that MAGE gene expression is frequent in HCC, thus suggesting that HCC patients may be good candidates for specific immunotherapy using MAGE peptides.",
author = "Kouichirou Tahara and Masaki Mori and Noriaki Sadanaga and Yoshihiro Sakamoto and Seigo Kitano and Masatoshi Makuuchi",
year = "1999",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7",
language = "English",
volume = "85",
pages = "1234--1240",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Expression of the MAGE gene family in human hepatocellular carcinoma

AU - Tahara, Kouichirou

AU - Mori, Masaki

AU - Sadanaga, Noriaki

AU - Sakamoto, Yoshihiro

AU - Kitano, Seigo

AU - Makuuchi, Masatoshi

PY - 1999/3/15

Y1 - 1999/3/15

N2 - BACKGROUND. The 12 members of the MAGE gene family encode tumor specific antigens that are recognized by autologous cytotoxic T lymphocytes (CTL). The MAGE genes are expressed not only in melanoma but in the other malignant tumors as well. There is, however, little information on their expression in hepatocellular carcinoma (HCC). The authors thus studied the expression of the MAGE gene family in human HCC and discuss the possibility of specific immunotherapy using MAGE peptides. METHODS. Tumor tissue samples of HCC and paired nontumor tissues of the liver were obtained from 22 HCC patients. Total RNA was extracted and cDNA was synthesized. Polymerase chain reaction amplification using each MAGE gene specific primer was then performed to detect the expression of each MAGE gene. Immunoblotting and immunohistochemical analysis were performed to confirm the expression of MAGE-3 gene product in HCC. RESULTS. The expression rate of each MAGE gene was as follows: MAGE-1 and -3 were expressed in approximately 68% of the tumors; MAGE-8 was expressed in 46%; and MAGE-2, -6, -10, -11, and -12 were expressed in approximately 30%. Nineteen (86%) of 22 tumors expressed at least 1 MAGE gene. On the other hand, no expression was detected in the noncarcinomatous liver tissue specimens. Actual expression of the gene product of MAGE-3 was detected in 50% of tumors. Clinicopathologic data on the MAGE positive and negative cases were compared. Significant differences were observed between MAGE expression status and a few clinicopathologic factors; however, further investigation is required to elucidate these correlations completely. CONCLUSIONS. These findings demonstrated that MAGE gene expression is frequent in HCC, thus suggesting that HCC patients may be good candidates for specific immunotherapy using MAGE peptides.

AB - BACKGROUND. The 12 members of the MAGE gene family encode tumor specific antigens that are recognized by autologous cytotoxic T lymphocytes (CTL). The MAGE genes are expressed not only in melanoma but in the other malignant tumors as well. There is, however, little information on their expression in hepatocellular carcinoma (HCC). The authors thus studied the expression of the MAGE gene family in human HCC and discuss the possibility of specific immunotherapy using MAGE peptides. METHODS. Tumor tissue samples of HCC and paired nontumor tissues of the liver were obtained from 22 HCC patients. Total RNA was extracted and cDNA was synthesized. Polymerase chain reaction amplification using each MAGE gene specific primer was then performed to detect the expression of each MAGE gene. Immunoblotting and immunohistochemical analysis were performed to confirm the expression of MAGE-3 gene product in HCC. RESULTS. The expression rate of each MAGE gene was as follows: MAGE-1 and -3 were expressed in approximately 68% of the tumors; MAGE-8 was expressed in 46%; and MAGE-2, -6, -10, -11, and -12 were expressed in approximately 30%. Nineteen (86%) of 22 tumors expressed at least 1 MAGE gene. On the other hand, no expression was detected in the noncarcinomatous liver tissue specimens. Actual expression of the gene product of MAGE-3 was detected in 50% of tumors. Clinicopathologic data on the MAGE positive and negative cases were compared. Significant differences were observed between MAGE expression status and a few clinicopathologic factors; however, further investigation is required to elucidate these correlations completely. CONCLUSIONS. These findings demonstrated that MAGE gene expression is frequent in HCC, thus suggesting that HCC patients may be good candidates for specific immunotherapy using MAGE peptides.

UR - http://www.scopus.com/inward/record.url?scp=0033559628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033559628&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7

DO - 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7

M3 - Article

C2 - 10189127

AN - SCOPUS:0033559628

VL - 85

SP - 1234

EP - 1240

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -